Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1775 and Belinostat in Relapsed/Refractory Myeloid Malignancies and Untreated AML
NCT02381548Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoint: Recommended Phase 2 Dose at 21 days. Started Aug 2015; status: terminated.
02
Drugs
adavosertib
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02381548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381548.